{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:36:37Z","timestamp":1789983397306,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pcad.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T15:09:27Z","timestamp":1753542567000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Transthyretin amyloid cardiomyopathy: Evolving therapies, expanding hope"],"prefix":"10.1016","volume":"92","author":[{"given":"Juan Pablo","family":"Costabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Leonardo","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Rochlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Berrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.07.011_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pcad.2024.01.013","article-title":"Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy","volume":"82","author":"Vaishnav","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.07.011_bb0010","article-title":"Performance of clinical scoring systems in the diagnosis of transthyretin amyloid cardiomyopathy in a diverse patient cohort","author":"Greenberg","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2025.07.011_bb0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pcad.2023.07.003","article-title":"Insight into different phenotypic presentations of heart failure with preserved ejection fraction","volume":"79","author":"Bashir","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2025.07.011_bb0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators, Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0025","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.07.011_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.07.011_bb0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.07.011_bb0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.07.011_bb0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jjcc.2023.02.009","article-title":"Prevalence of ventricular arrhythmias and role of implantable cardioverter-defibrillator in cardiac amyloidosis","volume":"81","author":"Bukhari","year":"2023","journal-title":"J Cardiol"},{"key":"10.1016\/j.pcad.2025.07.011_bb0050","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1002\/ehf2.14039","article-title":"Two-year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis","volume":"9","author":"Lim","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.pcad.2025.07.011_bb0055","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.07.011_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.healun.2021.10.007","article-title":"Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies","volume":"41","author":"Griffin","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2025.07.011_bb0065","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.pcad.2025.07.011_bb0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0075","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.07.011_bb0090","article-title":"HELIOS-B Trial Investigators, Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy, N","author":"Fontana","year":"2024","journal-title":"Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.pcad.2025.07.011_bb0105","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"NEURO-TTRansform Investigators, Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2025.07.011_bb0110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/lv.2000.6145","article-title":"Liver transplantation for hereditary transthyretin amyloidosis","volume":"6","author":"Suhr","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.pcad.2025.07.011_bb0115","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"issue":"24","key":"10.1016\/j.pcad.2025.07.011_bb0120","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2025.07.011_bb0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pcad.2025.07.011_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2025.07.011_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2025.07.011_bb0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.pcad.2025.07.011_bb0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.pcad.2025.07.011_bb0150","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"Jan Grimm, A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pcad.2025.07.011_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0160","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.07.011_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.pcad.2025.07.011_bb0170","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2459\/JCM.0000000000001192","article-title":"Compassionate drug use for patients with transthyretin amyloid cardiomyopathy","volume":"22","author":"Ciliberti","year":"2021","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.pcad.2025.07.011_bb0175","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.07.011_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:14:35Z","timestamp":1763183675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"alternative-id":["S0033062025001100"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.07.011","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin amyloid cardiomyopathy: Evolving therapies, expanding hope","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}